Current Cardiovascular Imaging Reports

, Volume 4, Issue 3, pp 199–206

SPECT and Cardiac Resynchronization Therapy

Authors

    • Department of RadiologyEmory University School of Medicine
    • Department of CardiologyLeiden University Medical Center
    • The Interuniversity Cardiology Institute of The Netherlands
    • Cardiovascular InstituteUniversity of Pittsburgh Medical Center
    • Division of Nuclear CardiologyUniversity of Pittsburgh Medical Center
    • Department of RadiologyEmory University School of Medicine
Article

DOI: 10.1007/s12410-011-9075-7

Cite this article as:
Chen, J., Boogers, M.J., Soman, P. et al. Curr Cardiovasc Imaging Rep (2011) 4: 199. doi:10.1007/s12410-011-9075-7
  • 27 Views

Abstract

Cardiac resynchronization therapy (CRT) has proven benefits in patients with refractory heart failure including improved symptoms, exercise capacity, quality of life, and left ventricular (LV) function, and mortality benefits. At present, CRT is recommended in patients with severe refractory heart failure (New York Heart Association class III or IV), LV ejection fraction ≤ 35%, QRS duration ≥ 120 ms, and sinus rhythm. When selected based on these standard indications, 20% to 40% of patients fail to respond to CRT. Important parameters for predicting CRT response, such as LV mechanical dyssynchrony, myocardial scar, and LV pacing lead position, have been studied using phase analysis of gated single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI). This review aims to describe the role of gated SPECT MPI for the comprehensive assessment of those parameters for selection of patients for CRT.

Keywords

Cardiac resynchronization therapyMyocardial perfusion imagingSPECTPhase analysis

Copyright information

© Springer Science+Business Media, LLC 2011